FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050084844> ?p ?o ?g. }

• W2050084844 endingPage "574" @default.
• W2050084844 startingPage "567" @default.
• W2050084844 abstract "We investigated the correlation between metabolic response by ¹⁸F-FDG PET and objective response, glucose transporter type 4 (GLUT4) expression, and <i>KIT/PDGFRA</i> mutation status in patients with gastrointestinal stromal tumor undergoing neoadjuvant imatinib mesylate therapy. <b>Methods:</b>¹⁸F-FDG PET was performed at baseline, 1–7 d, and 4 or 8 wk after imatinib mesylate initiation. Best objective response was defined by version 1.0 of the Response Evaluation Criteria in Solid Tumors (RECIST). Mutational analysis and tumor GLUT4 expression by immunohistochemistry were done on tissue obtained at baseline or surgery. <b>Results:</b>¹⁸F-FDG PET showed high baseline tumor glycolytic activity (mean SUV_max, 14.2; range, 1.3–53.2), decreasing after 1 wk of imatinib mesylate (mean, 5.5; range, −0.5–47.7, <i>P</i> < 0.001, <i>n</i> = 44), and again before surgery (mean, 3.0; range, −0.5–36.1, <i>P</i> < 0.001, <i>n</i> = 40). At week 1, there were 3 patients with complete metabolic response (CMR), 33 with partial metabolic response (PMR), 6 with stable metabolic disease (SMD), and 2 with progressive metabolic disease (PMD). Before surgery, there were 3 with CMR, 33 with PMR, 4 with SMD, and none with PMD. The best response according to RECIST was 2 with partial response, 36 with stable disease, and 1 with progressive disease (<i>n</i> = 39). Of the patients with a posttreatment decrease in GLUT4 expression, 1 had CMR, 15 had PMR, 2 had SMD, and 1 had PMD at week 1, whereas before surgery 1 patient had CMR, 16 had PMR, 2 had SMD, and none had PMD. Among 27 patients with <i>KIT</i> exon 11 mutations, 1 had CMR, 22 had PMR, 3 had SMD, and 1 had PMD at week 1, whereas 1 had CMR, 22 had PMR, 2 had SMD, and 2 were unknown before surgery; among 4 patients with a wild-type genotype, 2 had PMR and 2 SMD at week 1, whereas 1 had CMR, 2 had PMR, and 1 had SMD before surgery. <b>Conclusion:</b> After imatinib mesylate initiation, metabolic response by ¹⁸F-FDG PET was documented earlier (1–7 d) and was of much greater magnitude (36/44) than that documented by RECIST (2/39). Immunohistochemistry data suggest that GLUT4 may play a role in ¹⁸F-FDG uptake in gastrointestinal stromal tumor, GLUT4 levels decrease after imatinib mesylate therapy in most patients with PMR, and the biologic action of imatinib mesylate interacts with glycolysis and GLUT4 expression. A greater than 85% metabolic response was observed as early as days 1–7 in patients with exon 11 mutations." @default.
• W2050084844 created "2016-06-24" @default.
• W2050084844 creator A5020702257 @default.
• W2050084844 creator A5024815950 @default.
• W2050084844 creator A5027911766 @default.
• W2050084844 creator A5030584988 @default.
• W2050084844 creator A5033625395 @default.
• W2050084844 creator A5034360539 @default.
• W2050084844 creator A5049988109 @default.
• W2050084844 creator A5055455443 @default.
• W2050084844 creator A5077388635 @default.
• W2050084844 creator A5085744275 @default.
• W2050084844 creator A5086673871 @default.
• W2050084844 creator A5087008342 @default.
• W2050084844 creator A5091383750 @default.
• W2050084844 date "2012-03-01" @default.
• W2050084844 modified "2023-10-16" @default.
• W2050084844 title "ACRIN 6665/RTOG 0132 Phase II Trial of Neoadjuvant Imatinib Mesylate for Operable Malignant Gastrointestinal Stromal Tumor: Monitoring with ¹⁸F-FDG PET and Correlation with Genotype and GLUT4 Expression" @default.
• W2050084844 cites W1983787984 @default.
• W2050084844 cites W1995768812 @default.
• W2050084844 cites W1996411872 @default.
• W2050084844 cites W2002060029 @default.
• W2050084844 cites W2015015957 @default.
• W2050084844 cites W2020359163 @default.
• W2050084844 cites W2032157317 @default.
• W2050084844 cites W2039907242 @default.
• W2050084844 cites W2049103239 @default.
• W2050084844 cites W2055260008 @default.
• W2050084844 cites W2057470956 @default.
• W2050084844 cites W2068079378 @default.
• W2050084844 cites W2072451938 @default.
• W2050084844 cites W2101214437 @default.
• W2050084844 cites W2101986793 @default.
• W2050084844 cites W2105125481 @default.
• W2050084844 cites W2107078868 @default.
• W2050084844 cites W2107464631 @default.
• W2050084844 cites W2107651375 @default.
• W2050084844 cites W2107790510 @default.
• W2050084844 cites W2108549165 @default.
• W2050084844 cites W2113720689 @default.
• W2050084844 cites W2119238883 @default.
• W2050084844 cites W2122377651 @default.
• W2050084844 cites W2123534406 @default.
• W2050084844 cites W2139248078 @default.
• W2050084844 cites W2140626630 @default.
• W2050084844 cites W2150501295 @default.
• W2050084844 cites W2156143871 @default.
• W2050084844 cites W2169363650 @default.
• W2050084844 cites W2314511842 @default.
• W2050084844 doi "https://doi.org/10.2967/jnumed.111.094425" @default.
• W2050084844 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3635677" @default.
• W2050084844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22381410" @default.
• W2050084844 hasPublicationYear "2012" @default.
• W2050084844 type Work @default.
• W2050084844 sameAs 2050084844 @default.
• W2050084844 citedByCount "47" @default.
• W2050084844 countsByYear W20500848442012 @default.
• W2050084844 countsByYear W20500848442013 @default.
• W2050084844 countsByYear W20500848442014 @default.
• W2050084844 countsByYear W20500848442015 @default.
• W2050084844 countsByYear W20500848442016 @default.
• W2050084844 countsByYear W20500848442017 @default.
• W2050084844 countsByYear W20500848442018 @default.
• W2050084844 countsByYear W20500848442019 @default.
• W2050084844 countsByYear W20500848442020 @default.
• W2050084844 countsByYear W20500848442021 @default.
• W2050084844 countsByYear W20500848442022 @default.
• W2050084844 countsByYear W20500848442023 @default.
• W2050084844 crossrefType "journal-article" @default.
• W2050084844 hasAuthorship W2050084844A5020702257 @default.
• W2050084844 hasAuthorship W2050084844A5024815950 @default.
• W2050084844 hasAuthorship W2050084844A5027911766 @default.
• W2050084844 hasAuthorship W2050084844A5030584988 @default.
• W2050084844 hasAuthorship W2050084844A5033625395 @default.
• W2050084844 hasAuthorship W2050084844A5034360539 @default.
• W2050084844 hasAuthorship W2050084844A5049988109 @default.
• W2050084844 hasAuthorship W2050084844A5055455443 @default.
• W2050084844 hasAuthorship W2050084844A5077388635 @default.
• W2050084844 hasAuthorship W2050084844A5085744275 @default.
• W2050084844 hasAuthorship W2050084844A5086673871 @default.
• W2050084844 hasAuthorship W2050084844A5087008342 @default.
• W2050084844 hasAuthorship W2050084844A5091383750 @default.
• W2050084844 hasBestOaLocation W20500848441 @default.
• W2050084844 hasConcept C126322002 @default.
• W2050084844 hasConcept C143998085 @default.
• W2050084844 hasConcept C16930146 @default.
• W2050084844 hasConcept C2776694085 @default.
• W2050084844 hasConcept C2777007597 @default.
• W2050084844 hasConcept C2777583451 @default.
• W2050084844 hasConcept C2778729363 @default.
• W2050084844 hasConcept C2778822529 @default.
• W2050084844 hasConcept C2779984678 @default.
• W2050084844 hasConcept C2989005 @default.
• W2050084844 hasConcept C3019892230 @default.
• W2050084844 hasConcept C71924100 @default.
• W2050084844 hasConcept C90924648 @default.
• W2050084844 hasConceptScore W2050084844C126322002 @default.
• W2050084844 hasConceptScore W2050084844C143998085 @default.

• next